Market Place
Sourcing Support
Catamaran Announces Data from Allogeneic CAR-NK Cell Therapy Pipeline
11 Apr 2023 //
GLOBENEWSWIRE
Catamaran Bio selects OmniaBio as partner to develop CAR-NK cell therapies
14 Mar 2023 //
BUSINESSWIRE
Catamaran Bio, OmniaBio Partner to Advance Allogeneic CAR-NK Cell Therapies
14 Mar 2023 //
CONTRACT PHARMA
MaxCyte Signs Strategic Platform License with Catamaran Bio t
03 Jan 2023 //
GLOBENEWSWIRE
Catamaran Bio Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies
10 Nov 2022 //
BUSINESSWIRE
Catamaran SI Joint System Receives Review Board Approval for Post Market Studies
25 Oct 2022 //
ACCESSWIRE
Catamaran to Present Efficacy Data for Allogeneic CAR?NK Cell Therapies
05 Oct 2022 //
BUSINESSWIRE
Catamaran Bio Presents PC Data Supporting Novel Engineered CAR-NK Cell Therapies
16 May 2022 //
BUSINESSWIRE
Catamaran Bio to Present Preclinical Data at ASGCT for Solid Tumors
02 May 2022 //
BUSINESSWIRE
Catamaran Bio Appoints Cherry Thomas, MD, as Chief Medical Officer
27 Apr 2022 //
BUSINESSWIRE
Catamaran Bio Presents PC In Vivo Efficacy Data with Advancement of CAT?179
08 Apr 2022 //
BUSINESSWIRE
Catamaran Bio Appoints Frank Lee as Chair of Its Board of Directors
05 Apr 2022 //
BUSINESSWIRE
Catamaran Bio Expands Collaboration for with the University of Minnesota
14 Mar 2022 //
BUSINESSWIRE
Catamaran Bio to Present Efficacy Data on Allogeneic Solid Tumor CAR-NK Program
09 Mar 2022 //
BUSINESSWIRE
Catamaran Bio Presents PC Data Supporting CAT-248 in CD70-Expressing Cancers
13 Dec 2021 //
BUSINESSWIRE
Catamaran Bio Appoints Tara Place as VP, HR and Organizational Effectiveness
15 Nov 2021 //
BUSINESSWIRE
Catamaran Bio Announces Lead CAR-NK Cell Therapy Programs and Upcoming Data
04 Nov 2021 //
BUSINESSWIRE
Catamaran Appoints Joseph Gold as V.P Technical Operations and Manufacturing
02 Aug 2021 //
BUSINESS WIRE
Catamaran Bio and Bio-Techne Announce Expanded Collaboration
26 Jun 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.